N Z Med J 129 [PubMed] 16.Kotilea K, Quennery S, Decros V, Hermans DA (2014) Successful sublingual cobalamin treatment in a child with short-bowel syndrome
Gastrointestinal Integrity and Mucosal Protection Models Because BPC-157 was originally identified as a gastric pentadecapeptide, gastrointestinal biology remains a central focus of its experimental literature
According to Harvard Medical School, people with cobalamin deficiency may experience subtle but unusual and progressive signs of illness, including strange tingling or numb sensations, difficulty walking, cognitive and memory issues, and weakness
Contrary to popular fad diets that tend to lead to muscle loss and reduced metabolism, injectable treatments maintain a healthier and more scientific alternative by balancing pivotal hormones and biological reactions
BPC-157 is not an FDA-approved drug in the United States or in most other jurisdictions worldwide
doi: 10.1016/j.bioactmat.2022.12.007